glp-1 neuroendocrine tumor GLP- 1R status using validated monoclonal antibody in 689 cases of neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades | Virchows Archiv Glucagon-like peptide 1 receptor agonists

A Cleveland Clinic analysis of nearly 8,000 patients found that discontinuing semaglutide and tirzepatide did not lead to significant immediate weight regain in clinical practice

Investigating unexplained fatigue in general practice with a particular focus on CFS/ME

we realized we really needed to invest in the discontinuation phase and boost up our weight maintenance programming." Promising results While individuals that take GLP-1 injectable drugs for weight loss can achieve impressive results,researchers have thrown cold water on the belief users can simply quit taking the drug and expect to keep the weight off

doi: 10.1016/j.tvjl.2011.03.005 79